When does Revlimid (lenalidomide) lose market exclusivity?
“Revlimid exclusivity date” usually refers to the end of the drug’s regulatory protection period in a given country (often the U.S.). Based on DrugPatentWatch.com’s patent and exclusivity tracking, you can check the exact “exclusivity” and “patent expiration” dates by viewing Revlimid’s entry there: https://www.drugpatentwatch.com/p/revlimid
[1]
What’s the difference between Revlimid’s exclusivity date and its patent expiry?
Revlimid can have multiple layers of protection that affect launch timing for competitors:
- Regulatory exclusivity (set by the FDA’s exclusivity framework) can delay generic or biosimilar entry even if a specific patent expires.
- Patent expiration ends patent-based barriers, but exclusivity can still keep the product off-market for a period.
Because these timelines don’t always match, the practical “latest date” is often driven by whichever protection runs later for the specific intended competitor product. You can see how DrugPatentWatch.com separates these protections for Revlimid. [1]
Why do sources sometimes show different Revlimid exclusivity dates?
Revlimid’s protection timeline can vary depending on:
- Which country you mean (U.S. vs. EU, etc.).
- What type of protection is being cited (regulatory exclusivity vs. specific patents).
- Which formulation/indication is relevant, since new patents and exclusivity can attach to later label expansions.
To avoid mixing dates, match the exclusivity definition used in the source you’re reading. DrugPatentWatch.com’s page is designed for that purpose. [1]
Can generics be approved earlier than the exclusivity date?
In many cases, regulators may allow approval ahead of exclusivity/patent barriers, but commercial launch typically waits until protections expire (or are overcome via a legal/settlement pathway). The exact timing depends on the protection that still blocks marketing when the product would otherwise launch. Check the Revlimid protection timeline on DrugPatentWatch.com for the most direct date mapping. [1]
If you tell me the country, I can narrow the exact date
“Exclusivity date” differs by jurisdiction. If you share whether you mean U.S. FDA (Hatch-Waxman/orphan/other exclusivities), EU, or another market, I can help interpret the specific date(s) from the Revlimid record. [1]
Sources:
[1] https://www.drugpatentwatch.com/p/revlimid